Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on Aridis Pharmaceuticals (ARDS – Research Report). The associated price target is $2.00.
Vernon Bernardino based his Buy rating of Aridis Pharmaceuticals on various compelling aspects. Key among these is the company’s significant advancements in monoclonal antibody (mAb) treatments for viral and bacterial infectious diseases, which have notably attracted the interest of external parties. Furthermore, Aridis’s potential for non-dilutive financing through derisked assets was also a significant factor. The company’s recent grant from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of a pan-coronavirus human mAb, in collaboration with Eitr Biologics, further underscored Aridis’s noteworthy potential in the sector.
The company’s AR-301, an investigational fully human mAb in Phase 3 clinical development, has shown promise in treating gram-positive Staphylococcus aureus infections in patients with various types of pneumonia. This treatment, alongside AR-501, an inhaled formulation of gallium citrate under development for chronic lung infections in cystic fibrosis patients, are both viewed as potential value creators for the company. Bernardino also highlighted the potential for lucrative partnership deals and anticipated positive updates from these programs in early 2024 as reasons for his Buy rating. He concluded that the shares of Aridis Pharmaceuticals represent an attractive value proposition.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Aridis Pharmaceuticals (ARDS) Company Description:
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
Read More on ARDS:
